Adidas Upgrades Full-Year Guidance

United States News News

Adidas Upgrades Full-Year Guidance
United States Latest News,United States Headlines
  • 📰 MarketWatch
  • ⏱ Reading Time:
  • 12 sec. here
  • 2 min. at publisher
  • 📊 Quality Score:
  • News: 8%
  • Publisher: 97%

By Andrea Figueras Adidas upgraded its full-year guidance on the back of Yeezy inventory reductions and a better-than-expected underlying business, despite a...

Adidas upgraded its full-year guidance on the back of Yeezy inventory reductions and a better-than-expected underlying business, despite a decline in revenue and operating profit in the third quarter.

The underlying operating profit--excluding any one-offs related to Yeezy and the underway strategic review--is now estimated around 100 million euros , up from a prior guidance around break-even level, the company said.

We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more:

MarketWatch /  🏆 3. in US

United States Latest News, United States Headlines

Similar News:You can also read news stories similar to this one that we have collected from other news sources.

Pfizer slumps after slashing full-year profit forecast on tumbling Covid salesPfizer said slumping demand for its Comirnaty covid vaccine and its Paxlovid antiviral treatment will mean sharply lower revenues for the full year.
Read more »

Pfizer cuts full-year outlook due to declining sales of Covid-19-related productsPfizer cuts full-year outlook due to declining sales of Covid-19-related productsShares of Pfizer are falling before the opening bell as the company cut its full-year outlook, citing declining sales of its COVID-19-related products. Pfizer Inc. now foresees 2023 revenue in a range of $58 billion to $61 billion. Its prior forecast was for $67 billion to $70 billion. It now projects full-year adjusted earnings between $1.
Read more »

Pfizer cuts full-year outlook due to declining sales of Covid-19-related productsPfizer cuts full-year outlook due to declining sales of Covid-19-related productsShares of Pfizer are falling before the opening bell as the company cut its full-year outlook, citing declining sales of its COVID-19-related products
Read more »

NetScout’s stock drops 20% after full-year outlook reducedNetScout’s stock drops 20% after full-year outlook reducedWallace Witkowski came to MarketWatch from the Associated Press in New York, where he covered the business of Big Pharma, after covering FDA regulation of many of the same companies, as well as medical devices, in the Washington, D.C., area.
Read more »

Orla lifts full-year guidanceOrla lifts full-year guidanceTSX- and NYSE-listed Orla Mining has increased its full-year guidance, after a better-than-expected performance from its Camino Rojo mine, in Mexico. The Camino Rojo oxide mine produced and sold 32 425 oz and 31 060 oz of gold, respectively, during the third quarter.
Read more »

J&J’s stock rallies after profit and sales rise above expectations, full-year outlook increasedJ&J’s stock rallies after profit and sales rise above expectations, full-year outlook increasedTomi Kilgore is MarketWatch's deputy investing and corporate news editor and is based in New York. You can follow him on Twitter TomiKilgore.
Read more »



Render Time: 2025-02-23 22:00:53